Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

At AstraZeneca our industry-leading pipeline includes investigational therapies in various stages of clinical development - from approved medicines to earlier-stage molecules in clinical trials.

AstraZeneca-sponsored or -directed trial New Molecular Entities (NMEs) and significant indications First major market regulatory submission date and submission status is provided for assets in Phase III or beyond.

17 – Pipeline: Oncology • An effective immune response is durable - possibly life-long • Cancer hijacks many immune pathways to escape destruction • Our robust pipeline allows identification of combinations that restore the immune response

1. AstraZeneca. Vaxzevria shown in expert review to provide equally effective protection against COVID-19 hospitalisation and death as mRNA vaccines [Last accessed: October 2022]. Available from: https://www.astrazeneca.com/media-centre/medical-releases/vaxzevria-shown-in-expert-review-to-provide-equally-effective-protection-against-covid-19 ...

Apr 14, 2023 · AstraZeneca will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research (AACR) Annual Meeting, 14 to 19 April 2023.

AstraZeneca Development Pipeline as at 10 February 2022 References to Notes and page numbers, and capitalised terms not defined in this supplement can be found in AstraZeneca’s Annual Report and Form 20-F Information 2021 at www.astrazeneca.com/annualreport2021.

By combining pioneering science, digital technologies, big data and AI with the skills and experience of talented people, our pipeline goes beyond traditional small molecules, monoclonal antibodies and peptides, to include nucleotide modalities such as antisense oligonucleotides.

An exciting pipeline. Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Apr 25, 2024 · “AstraZeneca had a very strong start in 2024 with substantial Total Revenue growth of 19% in the first quarter. Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer, the data from both of these studies will be presented during the ASCO ...